NeuVax worht BILLIONS and $4.00 target reiterated ...again
Roughly 200 female patients were treated during the two phase 2 studies for NeuVax, and those who received the vaccine saw a 50% reduction in recurrence. The vaccine was even more effective when booster doses were utilized. This indicates that the vaccine can be used in several different ways, and thus, increases its market potential. The potential for billions in annual revenue resulted in one of the world's best-known capital markets investment banks, Cantor Fitzgerald, reiterating its "Buy" rating and a $4.00 price target for Galena Biopharma.
People can #$%$ talk the stock all they want- but the facts still remain that the science is real and proven, analysts are reiterating buy ratings and a nice price target, and the stock is staying strong in an overall down market. So... in other words, I agree with you that neuvax is worth in the billions. lol.
People don't realize how substantial these results are. A lot of blockbuster cancer drugs only increase survival 4 months. With a little more tweaking for waking up the immune system and we are off to the races.